A Prospective, Observational Study of Conversion From Immediate- to Prolonged-Release Tacrolimus in Renal Transplant Recipients in France: The OPALE Study

被引:5
作者
Moal, Valerie [1 ]
Grimbert, Philippe [2 ,3 ]
Beauvais, Adrien [4 ]
Dubel, Laurence [5 ]
Le Meur, Yann [6 ]
机构
[1] Aix Marseille Univ, Concept Hosp, AP HM, Nephrol & Kidney Transplantat Ctr, Marseille, France
[2] Henry Mondor Hosp, Nephrol & Transplantat Unit, Creteil, France
[3] UPEC Univ, Creteil, France
[4] RCTs, Lyon, France
[5] Astellas Pharma, Levallois Perret, France
[6] Cavale Blanches Hosp, Nephrol & Transplantat Unit, Brest, France
关键词
Kidney Transplantation; Observational Study; Tacrolimus; NOVO KIDNEY-TRANSPLANTATION; TWICE-DAILY TACROLIMUS; PHARMACOKINETICS; FORMULATIONS; EFFICACY; SAFETY;
D O I
10.12659/AOT.916043
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Potential benefits of once-daily, prolonged-release tacrolimus over the immediate-release formulation include improved adherence to immunosuppressives post transplantation. An observational study was performed to characterize real-world practice surrounding conversion from immediate- to prolonged-release tacrolimus in kidney transplant recipients. Material/Methods: We performed a prospective, observational study of renal transplant recipients converted from immediate- to prolonged-release tacrolimus capsules. Conversion took place at the baseline visit, within the first 6 months of transplantation (early conversion group) or between 6 and 12 months of transplantation (late conversion group). Data collection was performed at routine follow-up at 6 and 12 months. Endpoints included conversion ratio from immediate- to prolonged-release tacrolimus, reasons for conversion, additional visits due to conversion, safety, and tolerability. Results: The analysis population comprised 591 patients. Baseline characteristics were similar between the 2 groups. The mean conversion ratio of the daily dose of tacrolimus was 0.98 +/- 0.17 in the early group and 0.99+0.09 in the late group. Time from conversion (mean +/- SD) to first measurement of trough tacrolimus blood concentration was 12.1 +/- 11.6 and 27.6 +/- 26.7 days in the early and late groups, respectively. The highest number of additional visits required was 6 in the early conversion group, in 3 patients (0.7%), and 3 in the late conversion group, in 2 patients (1.6%). Conversion from immediate- to prolonged-release tacrolimus was associated with a very low rate of graft rejection. Conclusions: Favorable clinical outcomes and safety profiles were observed with conversion from immediate- to prolonged- release tacrolimus over 1 year following renal transplantation, with no marked differences between the early and late conversion groups.
引用
收藏
页码:517 / 526
页数:10
相关论文
共 24 条
[1]   Comparing the EQ-5D 3L and 5L: measurement properties and association with chronic conditions and multimorbidity in the general population [J].
Agborsangaya, Calypse B. ;
Lahtinen, Markus ;
Cooke, Tim ;
Johnson, Jeffrey A. .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2014, 12
[2]  
Agence de la biomedecine, 2017, RAPP MED SCI PREL GR
[3]  
[Anonymous], 2012, SUMM PROD CHAR
[4]  
Astellas Pharma Ltd, 2019, PROGRAF 05MG HARD CA
[5]   Frequency and impact of nonadherence to immunosuppressants after renal transplantation: A systematic review [J].
Butler, JA ;
Roderick, P ;
Mullee, M ;
Mason, JC ;
Peveler, RC .
TRANSPLANTATION, 2004, 77 (05) :769-776
[6]   Advagraf®, a once-daily prolonged release tacrolimus formulation, in kidney transplantation: literature review and guidelines from a panel of experts [J].
Caillard, Sophie ;
Moulin, Bruno ;
Buron, Fanny ;
Mariat, Christophe ;
Audard, Vincent ;
Grimbert, Philippe ;
Marquet, Pierre .
TRANSPLANT INTERNATIONAL, 2016, 29 (08) :860-869
[7]   Efficacy and Safety of Conversion from Twice-daily to Once-daily Tacrolimus in a Large Cohort of Stable Kidney Transplant Recipients [J].
Guirado, L. ;
Cantarell, C. ;
Franco, A. ;
Huertas, E. G. ;
Fructuoso, A. S. ;
Fernandez, A. ;
Gentil, M. A. ;
Rodriguez, A. ;
Paul, J. ;
Torregrossa, J. V. ;
Rodriguez, A. ;
Alonso, A. ;
Hernandez, D. ;
Burgos, D. ;
Jimenez, C. ;
Jimeno, L. ;
Lauzurica, R. ;
Mazuecos, A. ;
Osuna, A. ;
Plumed, J. S. ;
Ruiz, J. C. ;
Zarraga, S. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 (09) :1965-1971
[8]   OPTN/SRTR 2015 Annual Data Report: Kidney [J].
Hart, A. ;
Smith, J. M. ;
Skeans, M. A. ;
Gustafson, S. K. ;
Stewart, D. E. ;
Cherikh, W. S. ;
Wainright, J. L. ;
Kucheryavaya, A. ;
Woodbury, M. ;
Snyder, J. J. ;
Kasiske, B. L. ;
Israni, A. K. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 :21-116
[9]  
James Alexandra, 2015, Curr Transplant Rep, V2, P113
[10]  
Jannot Martin, 2014, Ann Transplant, V19, P320, DOI 10.12659/AOT.890262